GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 11.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,777 shares of the company’s stock after selling 4,165 shares during the quarter. Candriam S.C.A.’s holdings in GE HealthCare Technologies were worth $2,406,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. D1 Capital Partners L.P. acquired a new stake in shares of GE HealthCare Technologies in the 3rd quarter valued at approximately $268,159,000. Van ECK Associates Corp lifted its holdings in shares of GE HealthCare Technologies by 107.3% in the 4th quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock valued at $378,520,000 after buying an additional 2,506,417 shares during the period. State Street Corp lifted its holdings in shares of GE HealthCare Technologies by 7.8% in the 3rd quarter. State Street Corp now owns 18,615,890 shares of the company’s stock valued at $1,747,101,000 after buying an additional 1,347,114 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in shares of GE HealthCare Technologies in the 3rd quarter valued at approximately $93,713,000. Finally, Jennison Associates LLC lifted its holdings in shares of GE HealthCare Technologies by 124.5% in the 4th quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock valued at $133,659,000 after buying an additional 948,017 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance

GE HealthCare Technologies stock opened at $86.58 on Monday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04. The stock has a fifty day moving average of $86.77 and a two-hundred day moving average of $86.16. The company has a market capitalization of $39.59 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. On average, analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Citigroup raised their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Wells Fargo & Company raised their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.